[{"data":1,"prerenderedAt":228},["ShallowReactive",2],{"$fwjcv40wdu5x9":3},{"schema":4,"slug":5,"series":6,"series_slug":7,"name":8,"year":9,"therapeutic_area":10,"generated_at":11,"counts":12,"top_targets":22,"top_modalities":54,"top_diseases":78,"top_companies":104,"key_results":126,"trends":215,"previous_editions":224,"comparison":131,"highlighted_classes":225},1,"esmo-io-2025","ESMO IO","esmo-io","ESMO Immuno-Oncology Congress 2025",2025,"Oncology","2026-11-05T22:19:09Z",{"abstracts":13,"drug_linked":14,"companies":15,"by_phase":16},603,304,90,{"Phase 1":17,"Phase 1\u002F2":18,"Phase 2":19,"Phase 4":20,"Phase 2\u002F3":20,"Phase 3":21},21,16,73,2,43,[23,27,31,35,37,40,43,45,47,51],{"name":24,"count":25,"share":26},"PDCD1",55,18,{"name":28,"count":29,"share":30},"EGFR",31,10,{"name":32,"count":33,"share":34},"CD274",26,9,{"name":36,"count":33,"share":34},"ERBB2",{"name":38,"count":18,"share":39},"TUBB",5,{"name":41,"count":42,"share":39},"MET",14,{"name":44,"count":42,"share":39},"VEGFR2",{"name":46,"count":42,"share":39},"VEGFR4",{"name":48,"count":49,"share":50},"VEGFR-1",13,4,{"name":52,"count":53,"share":50},"RET",12,[55,59,62,65,67,70,73,75],{"name":56,"count":57,"share":58},"Small molecules",153,50,{"name":60,"count":61,"share":29},"Monoclonal antibodies",93,{"name":63,"count":64,"share":34},"Antibody-drug conjugates",28,{"name":66,"count":42,"share":39},"Bispecific antibodies",{"name":68,"count":69,"share":20},"Non-antibody therapeutic proteins",7,{"name":71,"count":72,"share":20},"Natural-product mixtures and botanicals",6,{"name":74,"count":39,"share":20},"Peptides",{"name":76,"count":77,"share":4},"Vaccines",3,[79,82,86,88,91,93,95,97,99,102],{"name":80,"count":81,"share":33},"non-small cell lung cancer (NSCLC)",78,{"name":83,"count":84,"share":85},"breast cancer",34,11,{"name":87,"count":26,"share":72},"gastric cancer (GC)",{"name":89,"count":90,"share":72},"hepatocellular carcinoma (HCC)",17,{"name":92,"count":49,"share":50},"head and neck squamous cell carcinoma (HNSCC)",{"name":94,"count":34,"share":77},"gastric adenocarcinoma",{"name":96,"count":34,"share":77},"gastroesophageal junction adenocarcinoma",{"name":98,"count":34,"share":77},"prostate cancer (PCa)",{"name":100,"count":101,"share":77},"colorectal cancer (CRC)",8,{"name":103,"count":101,"share":77},"pancreatic cancer (PC)",[105,108,110,112,114,116,118,120,122,124],{"name":106,"count":107,"share":30},"AstraZeneca",29,{"name":109,"count":26,"share":72},"Bristol Myers Squibb",{"name":111,"count":18,"share":39},"Merck",{"name":113,"count":30,"share":77},"Genentech",{"name":115,"count":30,"share":77},"Pfizer",{"name":117,"count":34,"share":77},"HUTCHMED",{"name":119,"count":34,"share":77},"Jiangsu HengRui Medicine Co., Ltd.",{"name":121,"count":101,"share":77},"Eisai",{"name":123,"count":101,"share":77},"Henlius",{"name":125,"count":69,"share":20},"BeiGene",[127,136,143,149,157,164,171,178,186,194,201,207],{"title":128,"drug":129,"company":131,"phase":132,"disease":133,"finding":134,"url":135},"A-BRAVE trial: a phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients",{"name":130,"slug":130},"avelumab",null,"Phase 3","triple-negative breast cancer (TNBC)","In a descriptive analysis, avelumab reduced the hazard of OS events: HR 0.66, 95% CI 0.45-0.97.","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.annonc.2025.08.005",{"title":137,"drug":138,"company":115,"phase":132,"disease":140,"finding":141,"url":142},"First-line (1L) encorafenib + cetuximab + mFOLFOX6 in East Asian patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC): Results from the phase III BREAKWATER study",{"name":139,"slug":139},"encorafenib","metastatic colon cancer (mCRC)","Median PFS by BICR was 14.0 vs 7.1 mo, and median OS was not estimable (NE) vs 13.7 mo for EC+mFOLFOX6 vs control.","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.annonc.2025.10.022",{"title":144,"drug":145,"company":106,"phase":132,"disease":89,"finding":147,"url":148},"Pooled efficacy and safety with tremelimumab plus durvalumab in participants (pts) with unresectable hepatocellular carcinoma (uHCC) from the mainland China extension cohort, and Hong Kong (HK) and Taiwan (TW) subgroups from the global cohort in the phase III HIMALAYA study",{"name":146,"slug":131},"durvalumab + tremelimumab","OS HRs (95% CI) were 0.60 (0.42–0.84) for STRIDE and 0.68 (0.49–0.96) for D vs S.","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.annonc.2025.10.101",{"title":150,"drug":151,"company":131,"phase":132,"disease":154,"finding":155,"url":156},"Tisotumab vedotin vs investigator’s choice of chemotherapy as second- or third-line (2L\u002F3L) treatment for Chinese patients (pts) with recurrent or metastatic cervical cancer (r\u002FmCC) in innovaTV 301",{"name":152,"slug":153},"tisotumab vedotin","tisotumab-vedotin","cervical cancer (mCC)","Median (95% CI) OS was not reached (9.7 months–not estimable) with TV vs 10.7 months (6.0-not estimable) with chemotherapy (HR 0.55; 95% CI 0.27–1.15).","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.annonc.2025.10.1046",{"title":158,"drug":159,"company":131,"phase":132,"disease":94,"finding":162,"url":163},"SHR-1701 plus CAPOX in patients with advanced gastric or gastroesophageal junction adenocarcinoma and PD-L1 combined positive score ≥1: A post-hoc analysis of a phase III study",{"name":160,"slug":161},"retlirafusp alfa","retlirafusp-alfa","Median OS was 16.7 months (95% CI, 14.4-18.5) in the SHR-1701 group versus 10.3 months (95% CI, 9.3-12.1) in the placebo group (HR=0.56; 95% CI, 0.45-0.71).","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.annonc.2025.10.125",{"title":165,"drug":166,"company":168,"phase":132,"disease":80,"finding":169,"url":170},"Plinabulin\u002Fdocetaxel vs. docetaxel in 2L\u002F3L EGFRwt NSCLC after platinum regimens (DUBLIN-3): Asian subgroup analysis",{"name":167,"slug":167},"plinabulin","BeyondSpring","At 24-months (Mo) follow-up after database lock (DB), the survival benefit persisted with mOS favoring DP (10.8 vs. 8.8 Mo, HR=0.80, p=0.0300), and more pronounced in non-squamous (NSQ) pts (11.4 vs. 8.4 Mo, HR=0.69, p=0.0064).","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.annonc.2025.10.691",{"title":172,"drug":173,"company":131,"phase":132,"disease":175,"finding":176,"url":177},"Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small-cell lung cancer (ES-SCLC): IMforte Asia subgroup results",{"name":174,"slug":174},"lurbinectedin","small cell lung cancer (SCLC)","At data cutoff (29 Jul 2024), IRF-PFS was improved with lurbi + atezo vs atezo (median, 6.3 vs 1.8 mo; unstratified HR, 0.48; 95% CI: 0.27, 0.87), as was OS (median, 16.5 vs 12.2 mo; unstratified HR, 0.81; 95% CI: 0.37, 1.75).","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.annonc.2025.10.692",{"title":179,"drug":180,"company":182,"phase":132,"disease":183,"finding":184,"url":185},"Safety profile of dabrafenib plus trametinib (D+T) in previously treated Chinese Mainland subgroup (CMS) population with radioactive iodine (RAI)–refractory BRAF V600E mutation–positive differentiated thyroid cancer (DTC)",{"name":181,"slug":131},"dabrafenib + trametinib","Novartis","well-differentiated thyroid cancer (WDTC)","The incidence of grade ≥3 AEs was higher in the D+T (52.8%) than the PBO arm (21.7%).","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.annonc.2025.10.357",{"title":187,"drug":188,"company":117,"phase":190,"disease":191,"finding":192,"url":193},"Surufatinib (S) in combination with camrelizumab (C), nab-paclitaxel and gemcitabine (AG) as the first-line treatment in metastatic pancreatic cancer: Results from phase II part of a randomized, open-label, active-controlled, phase II\u002FIII study",{"name":189,"slug":189},"surufatinib","Phase 2\u002F3","pancreatic cancer (PDAC)","With the median PFS follow-up duration of 8.15 months (m), S+C+AG demonstrated superior median PFS vs AG (7.20m vs 5.52m, stratified hazard ratio [HR] 0.499, log-rank P = 0.0407).","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.annonc.2025.10.201",{"title":195,"drug":196,"company":131,"phase":198,"disease":94,"finding":199,"url":200},"Efficacy and safety of adebrelimab combined with S-1 plus oxaliplatin in neoadjuvant therapy for locally advanced gastric adenocarcinoma",{"name":197,"slug":197},"adebrelimab","Phase 2","The ASO group achieved significantly higher pCR rates compared to PSO group (25.45% vs 1.82%, p\u003C0.0001), with marked tumor downstaging (ypT0: 25.45% vs 1.82%; ypN0: 65.45% vs 21.82%, both p\u003C0.0001).","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.annonc.2025.10.104",{"title":202,"drug":203,"company":131,"phase":198,"disease":140,"finding":205,"url":206},"Fruquintinib combined with TAS-102 with or without SBRT as third- or later-line treatment in metastatic colorectal cancer : Preliminary results from a prospective phase II trial",{"name":204,"slug":204},"fruquintinib","ORR was 36.4% (4\u002F11) in FTS vs 12% (3\u002F25) in FT,and mPFS was not reached in FTS vs 8.58 months (95% CI: 4.57–9.00) in FT.","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.annonc.2025.10.028",{"title":208,"drug":209,"company":211,"phase":212,"disease":80,"finding":213,"url":214},"Zongertinib in HER2-mutant advanced NSCLC: Impact of therapy line on efficacy",{"name":210,"slug":210},"zongertinib","Boehringer Ingelheim","Phase 1","In patients who received 3L zongertinib, the confirmed ORR was 75.0% (46.8–91.1)","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.annonc.2025.10.698",{"summary":216,"bullets":218},[217],"Small molecules were the most frequent modality (50% of drug-linked abstracts). PDCD1 was the most frequent target (18%). Non-small cell lung cancer (NSCLC) was the most frequent disease (26%).",[219,220,221,222,223],"AstraZeneca had the largest company share (10% of drug-linked abstracts).","Antibody-drug conjugates accounted for 9% of drug-linked abstracts.","Bispecific antibodies accounted for 5% of drug-linked abstracts.","Monoclonal antibodies were the next most frequent modality (31%).","EGFR was the next most frequent target (10%).",[],[226,227],{"name":63,"count":64,"share":34,"previous_count":131,"previous_share":131,"direction":131},{"name":66,"count":42,"share":39,"previous_count":131,"previous_share":131,"direction":131},1793970603100]